Aequus Pharmaceuticals (Aequus Pharmaceuticals) 3-Year EBITDA Growth Rate : -88.20% (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Aequus Pharmaceuticals 3-Year EBITDA Growth Rate?

Aequus Pharmaceuticals's EBITDA per Share for the three months ended in Mar. 2024 was $-0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was -88.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 7.00% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 22.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Aequus Pharmaceuticals was 62.10% per year. The lowest was -88.20% per year. And the median was 25.30% per year.

Competitive Comparison of Aequus Pharmaceuticals's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Aequus Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aequus Pharmaceuticals's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aequus Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Aequus Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.

Aequus Pharmaceuticals 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Aequus Pharmaceuticals (OTCPK:AQSZF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Aequus Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Aequus Pharmaceuticals's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Aequus Pharmaceuticals (Aequus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aequus Pharmaceuticals Inc (OTCPK:AQSZF) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

AEQ:Germany AQS:Canada

Address

200 Granville Street, Suite 2820, Vancouver, BC, CAN, V6C 1S4

Website

https://www.aequuspharma.ca

Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The Company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products, namely Tacrolimus IR and Vistitan.